BUTI, Sebastiano
BUTI, Sebastiano
Dipartimento di Medicina e Chirurgia
112 Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors
2022-01-01 Choucair, Khalil; Nebhan, Caroline; Cortellini, Alessio; Hentzen, Stijn; Wang, Yinghong; Salama, April; Elliott, Andrew; Oberley, Matthew; Walker, Phillip; Bokhari, Raza; Giusti, Raffaele; Filetti, Marco; Ascierto, Paolo; Vannella, Vito; Galetta, Domenico; Catino, Annamaria; Pizzutilo, Pamela; Genova, Carlo; Bersanelli, Melissa; Buti, Sebastiano; Saeed, Azhaar; El-Deiry, Wafik; Beltran, Himisha; Nabhan, Chadi; Johnson, Douglas; Fulgenzi, Claudia; Pinato, David; Radford, Maluki; Liu, Stephen; Kim, Chul; Naqash, Rafeh; Saeed, Anwaar
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
2024-01-01 Mazzaschi, G.; Marrocchio, C.; Moron Dalla Tor, L.; Leo, L.; Dodi, A.; Tamarozzi, P.; Balbi, M.; Milanese, G.; Monica, G.; D'Agnelli, S.; Lorusso, B.; Pluchino, M.; Minari, R.; Leonetti, A.; Bordi, P.; Perrone, F.; Buti, S.; Quaini, F.; Roti, G.; Sverzellati, N.; Tiseo, M.
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
2021-01-01 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
2022-01-01 Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Ermacora, P.; Maiorano, B. A.; Prati, V.; De Giorgi, U. F. F.; Pierantoni, F.; Malgeri, A.; Mennitto, A.; Cavo, A.; Vitale, M. G.; Santoni, M.; Carella, C.; Procopio, G.; Verzoni, E.; Santini, D.
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study
2022-01-01 Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Catalano, F.; Murianni, V.; Cremante, M.; Damassi, A.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G.
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
2023-01-01 Leonetti, Null; Peroni, M.; Agnetti, V.; Pratticò, F.; Manini, M.; Acunzo, A.; Marverti, F.; Sulas, S.; Rapacchi, E.; Mazzaschi, G.; Perrone, F.; Bordi, P.; Buti, S.; Tiseo, M.
1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
2024-01-01 Catalano, M.; Roviello, G.; Buti, S.; Massari, F.; Li, H.; Park, S. H.; Grande, E.; Kucharz, J.; Fiala, O.; Poprach, A.; Buchler, T.; Seront, E.; Ansari, J.; Myint, Z. W.; Bhuva, D. M.; Bamias, A.; Ghosn, M.; Andrey, S.; Santoni, M.; Santini, D.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
2021-01-01 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
2023-01-01 Iacovelli, R.; Ciccarese, C.; Bersanelli, M.; Zucali, P. A.; Fantinel, E.; Bimbatti, D.; Verzoni, E.; Accettura, C.; Bonomi, L.; Buttigliero, C.; G. fornarini, Null; Pipitone, S.; Atzori, F.; Masini, C.; Massari, F.; Primi, F.; Buti, S.; Perrino, M. R. A.; Pafumi, S.; Tortora, G.
1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
2023-01-01 Rebuzzi, S. E.; Signori, A.; Buti, S.; Maruzzo, M.; De Giorgi, U. F. F.; Zucali, P. A.; Procopio, G.; Fratino, L.; Pipitone, S.; Mollica, V.; Soraru, M.; Chiellino, S.; Lipari, H.; Galli, L.; Masini, C.; Naglieri, E.; Milella, M.; Ricotta, R.; Banna, G. L.; Fornarini, G.
1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023-01-01 Massari, F.; Pulido, E. Grande; Bamias, A.; Iacovelli, R.; Cerrillo, J. Molina; Procopio, G.; Fiala, O.; Myint, Z. W.; De Giorgi, U. F. F.; Buchler, T.; Santini, D.; Büttner, T.; Roviello, G.; Pichler, M.; Bourlon de los Rios, M. T.; Rizzo, A.; Monteiro, F. S. M.; Buti, S.; Porta, C. G.; Santoni, M.
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)
2023-01-01 Verzoni, E.; Procopio, G.; Bottiglieri, A.; Stellato, M.; Rametta, A.; Zucali, P. A.; Perrucci, B.; G. fornarini, Null; Buti, S.; Maruzzo, M.; Cova, A.; Squarcina, P.; Lalli, L.; Mereu, A.; Cerioli, N.; Agnelli, L.; Todoerti, K.; Busico, A.; Rivoltini, L.; Huber, V.
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
2020-01-01 Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M.
1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
2024-01-01 Stellato, M.; Giannatempo, P.; Polymeropoulos, A.; Guadalupi, V.; Claps, M.; Ambrosini, P.; Raggi, D.; Rametta, A.; Cavalli, C.; Gusmaroli, E.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A.
2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
2024-01-01 Giannatempo, P.; Polymeropoulos, A.; Stellato, M.; Ambrosini, P.; Gusmaroli, E.; Cavalli, C.; Guadalupi, V.; Claps, M.; Raggi, D.; Rametta, A.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A.
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
2023-01-01 Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Giudice, G. C.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M.
2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
2023-01-01 Giannatempo, P.; Bottiglieri, A.; Guadalupi, V.; Marandino, L.; Raggi, D.; Stellato, M.; Rametta, A.; Baciarello, G.; Sepe, P.; Claps, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Cattaneo, L.; Verzoni, E.; Ortega, C.; Procopio, G.; Necchi, A.
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
2022-01-01 Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial
2007-01-01 Chiesa, Md; Passalacqua, R; Michiara, M; Franciosi, V; Di Costanzo, F; Bisagni, G; Camisa, R; Buti, S; Tomasello, G; Cocconi, G; Italian Oncology Group for Clinical, Research.
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors
2022-01-01 Pecci, Federica; Cantini, Luca; Cognigni, Valeria; Perrone, Fabiana; Agostinelli, Veronica; Mazzaschi, Giulia; Favari, Elda; Maffezzoli, Michele; Cortellini, Alessio; Rossi, Francesca; Chiariotti, Rebecca; Venanzi, Francesco; Mentrasti, Giulia; Russo, Giuseppe Lo; Galli, Giulia; Proto, Claudia; Ganzinelli, Monica; Tronconi, Francesca; Morgese, Francesca; Campolucci, Carla; Moretti, Marco; Vignini, Arianna; Bersanelli, Melissa; Buti, Sebastiano; Berardi, Rossana
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 112 Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors | 1-gen-2022 | Choucair, Khalil; Nebhan, Caroline; Cortellini, Alessio; Hentzen, Stijn; Wang, Yinghong; Salama, April; Elliott, Andrew; Oberley, Matthew; Walker, Phillip; Bokhari, Raza; Giusti, Raffaele; Filetti, Marco; Ascierto, Paolo; Vannella, Vito; Galetta, Domenico; Catino, Annamaria; Pizzutilo, Pamela; Genova, Carlo; Bersanelli, Melissa; Buti, Sebastiano; Saeed, Azhaar; El-Deiry, Wafik; Beltran, Himisha; Nabhan, Chadi; Johnson, Douglas; Fulgenzi, Claudia; Pinato, David; Radford, Maluki; Liu, Stephen; Kim, Chul; Naqash, Rafeh; Saeed, Anwaar | |
| 1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients | 1-gen-2024 | Mazzaschi, G.; Marrocchio, C.; Moron Dalla Tor, L.; Leo, L.; Dodi, A.; Tamarozzi, P.; Balbi, M.; Milanese, G.; Monica, G.; D'Agnelli, S.; Lorusso, B.; Pluchino, M.; Minari, R.; Leonetti, A.; Bordi, P.; Perrone, F.; Buti, S.; Quaini, F.; Roti, G.; Sverzellati, N.; Tiseo, M. | |
| 1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy | 1-gen-2021 | Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M. | |
| 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) | 1-gen-2022 | Stellato, M.; Buti, S.; Maruzzo, M.; Bersanelli, M.; Ermacora, P.; Maiorano, B. A.; Prati, V.; De Giorgi, U. F. F.; Pierantoni, F.; Malgeri, A.; Mennitto, A.; Cavo, A.; Vitale, M. G.; Santoni, M.; Carella, C.; Procopio, G.; Verzoni, E.; Santini, D. | |
| 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study | 1-gen-2022 | Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Catalano, F.; Murianni, V.; Cremante, M.; Damassi, A.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G. | |
| 1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study | 1-gen-2023 | Leonetti, Null; Peroni, M.; Agnetti, V.; Pratticò, F.; Manini, M.; Acunzo, A.; Marverti, F.; Sulas, S.; Rapacchi, E.; Mazzaschi, G.; Perrone, F.; Bordi, P.; Buti, S.; Tiseo, M. | |
| 1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) | 1-gen-2024 | Catalano, M.; Roviello, G.; Buti, S.; Massari, F.; Li, H.; Park, S. H.; Grande, E.; Kucharz, J.; Fiala, O.; Poprach, A.; Buchler, T.; Seront, E.; Ansari, J.; Myint, Z. W.; Bhuva, D. M.; Bamias, A.; Ghosn, M.; Andrey, S.; Santoni, M.; Santini, D. | |
| 17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study | 1-gen-2023 | Iacovelli, R.; Ciccarese, C.; Bersanelli, M.; Zucali, P. A.; Fantinel, E.; Bimbatti, D.; Verzoni, E.; Accettura, C.; Bonomi, L.; Buttigliero, C.; G. fornarini, Null; Pipitone, S.; Atzori, F.; Masini, C.; Massari, F.; Primi, F.; Buti, S.; Perrino, M. R. A.; Pafumi, S.; Tortora, G. | |
| 1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15) | 1-gen-2023 | Rebuzzi, S. E.; Signori, A.; Buti, S.; Maruzzo, M.; De Giorgi, U. F. F.; Zucali, P. A.; Procopio, G.; Fratino, L.; Pipitone, S.; Mollica, V.; Soraru, M.; Chiellino, S.; Lipari, H.; Galli, L.; Masini, C.; Naglieri, E.; Milella, M.; Ricotta, R.; Banna, G. L.; Fornarini, G. | |
| 1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations | 1-gen-2023 | Massari, F.; Pulido, E. Grande; Bamias, A.; Iacovelli, R.; Cerrillo, J. Molina; Procopio, G.; Fiala, O.; Myint, Z. W.; De Giorgi, U. F. F.; Buchler, T.; Santini, D.; Büttner, T.; Roviello, G.; Pichler, M.; Bourlon de los Rios, M. T.; Rizzo, A.; Monteiro, F. S. M.; Buti, S.; Porta, C. G.; Santoni, M. | |
| 1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) | 1-gen-2023 | Verzoni, E.; Procopio, G.; Bottiglieri, A.; Stellato, M.; Rametta, A.; Zucali, P. A.; Perrucci, B.; G. fornarini, Null; Buti, S.; Maruzzo, M.; Cova, A.; Squarcina, P.; Lalli, L.; Mereu, A.; Cerioli, N.; Agnelli, L.; Todoerti, K.; Busico, A.; Rivoltini, L.; Huber, V. | |
| 1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients | 1-gen-2020 | Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M. | |
| 1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis | 1-gen-2024 | Stellato, M.; Giannatempo, P.; Polymeropoulos, A.; Guadalupi, V.; Claps, M.; Ambrosini, P.; Raggi, D.; Rametta, A.; Cavalli, C.; Gusmaroli, E.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A. | |
| 2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) | 1-gen-2024 | Giannatempo, P.; Polymeropoulos, A.; Stellato, M.; Ambrosini, P.; Gusmaroli, E.; Cavalli, C.; Guadalupi, V.; Claps, M.; Raggi, D.; Rametta, A.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A. | |
| 2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study | 1-gen-2023 | Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Giudice, G. C.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M. | |
| 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial | 1-gen-2023 | Giannatempo, P.; Bottiglieri, A.; Guadalupi, V.; Marandino, L.; Raggi, D.; Stellato, M.; Rametta, A.; Baciarello, G.; Sepe, P.; Claps, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Cattaneo, L.; Verzoni, E.; Ortega, C.; Procopio, G.; Necchi, A. | |
| 238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors | 1-gen-2022 | Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial | 1-gen-2007 | Chiesa, Md; Passalacqua, R; Michiara, M; Franciosi, V; Di Costanzo, F; Bisagni, G; Camisa, R; Buti, S; Tomasello, G; Cocconi, G; Italian Oncology Group for Clinical, Research. | |
| 91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors | 1-gen-2022 | Pecci, Federica; Cantini, Luca; Cognigni, Valeria; Perrone, Fabiana; Agostinelli, Veronica; Mazzaschi, Giulia; Favari, Elda; Maffezzoli, Michele; Cortellini, Alessio; Rossi, Francesca; Chiariotti, Rebecca; Venanzi, Francesco; Mentrasti, Giulia; Russo, Giuseppe Lo; Galli, Giulia; Proto, Claudia; Ganzinelli, Monica; Tronconi, Francesca; Morgese, Francesca; Campolucci, Carla; Moretti, Marco; Vignini, Arianna; Bersanelli, Melissa; Buti, Sebastiano; Berardi, Rossana |